跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
林 子平
副教授
醫學系泌尿學科
電子郵件
tplin
vghtpe.gov
tw
h-index
h10-index
h5-index
1215
引文
17
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1153
引文
17
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
501
引文
10
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2025
每年研究成果
概覽
指紋
網路
研究成果
(75)
類似的個人檔案
(6)
指紋
查看啟用 Tzu-Ping Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Prostate Cancer
100%
Prostate Cancer Cells
38%
Neuroendocrine Prostate Cancer
37%
Prostate-specific Antigen
31%
Taiwan
30%
Monoamine Oxidase A (MAO-A)
29%
Prostate Health Index
29%
Prostate
27%
Magnetic Resonance Imaging
26%
Transperineal Prostate Biopsy
24%
Castration-resistant Prostate Cancer
23%
Radical Prostatectomy
22%
Upper Tract Urothelial Carcinoma
21%
Prostate Cancer Screening
20%
Taiwanese
20%
Multiparametric MRI (mpMRI)
20%
Benign Prostatic Hyperplasia
19%
Clinically Significant Prostate Cancer
18%
Escherichia Coli
18%
Neuroendocrine Differentiation
18%
Nephroureterectomy
17%
Robotic-assisted Partial Nephrectomy
17%
Prostate Health Index Density
17%
Lineage Plasticity
17%
Taipei
17%
General Hospital
17%
Urology
17%
Laparoscopic Partial Nephrectomy
16%
Tumor
16%
Complication Rate
16%
Renal Cell Carcinoma
14%
Risk Factors
14%
Non-muscle Invasive Bladder Cancer (NMIBC)
14%
Androgen Receptor Antagonist
14%
Postoperative Outcomes
14%
RE1-silencing Transcription Factor
13%
Bladder Cuff Excision
12%
Bacillus Calmette
12%
Prostate Tumor Growth
12%
Targeted Prostate Biopsy
12%
Growth Inhibition
12%
Disease-free Survival
12%
Wnt Signaling
11%
National Cohort Study
11%
High Power
11%
Thulium Laser
11%
Asia-Pacific
11%
Epigenetic Regulation
11%
Glycolysis
11%
Induced Growth
11%
Medicine and Dentistry
Prostate Cancer
92%
Neoplasm
43%
Prostate Biopsy
40%
Prostate Specific Antigen
38%
Biopsy Technique
34%
Transrectal Ultrasonography
29%
Clear Cell Renal Cell Carcinoma
25%
Partial Nephrectomy
25%
Prostatectomy
23%
Magnetic Resonance Imaging
23%
Transitional Cell Carcinoma
22%
Bladder
21%
Nephroureterectomy
17%
Malignant Neoplasm
16%
Amine Oxidase (Flavin Containing) Isoenzyme A
15%
Recurrent Disease
15%
Urology
15%
Non Muscle Invasive Bladder Cancer
15%
Gleason Score
13%
Prostate Hypertrophy
11%
Upper Urinary Tract
11%
Castration Resistant Prostate Cancer
11%
Wnt Signaling
11%
Thulium
11%
Overall Survival
11%
Bleeding
10%
Cancer Diagnosis
9%
Disease Free Survival
9%
Tumor Progression
9%
Biological Marker
9%
Metastatic Carcinoma
9%
Retrospective Study
9%
Body Mass Index
9%
Operation Duration
8%
Kidney Stone
8%
Heart Muscle Ischemia
8%
Kidney Function
8%
Nephrectomy
8%
Diseases
7%
Multiparametric Magnetic Resonance Imaging
7%
Extracorporeal Shock Wave Lithotripsy
7%
Outpatient
7%
Peroperative Complication
7%
Predictive Factor
7%
Adverse Event
7%
Enucleation
6%
Intravesical Drug Administration
6%
Targeted Therapy
6%
Stromal Cell
6%
Prostate Tumor
6%
